Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTC:AAWHNASDAQ:ALLONASDAQ:CADLNASDAQ:OLMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAWHAscend Wellness$0.30-4.7%$0.34$0.27▼$1.23$60.41M1.03119,357 shs58,328 shsALLOAllogene Therapeutics$1.37+2.2%$1.34$0.86▼$3.78$299.66M0.313.32 million shs1.76 million shsCADLCandel Therapeutics$5.16+0.6%$5.19$3.79▼$14.60$258.53M-0.871.47 million shs730,319 shsOLMAOlema Pharmaceuticals$4.19+0.5%$4.58$2.86▼$16.62$286.68M1.99820,649 shs1.11 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAWHAscend Wellness0.00%-7.66%-6.75%-17.92%-67.93%ALLOAllogene Therapeutics0.00%-5.63%+20.72%-27.57%-42.98%CADLCandel Therapeutics0.00%-15.07%-4.11%-41.90%-29.63%OLMAOlema Pharmaceuticals0.00%-6.50%-11.46%-6.29%-66.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAWHAscend Wellness1.1101 of 5 stars0.03.00.00.01.91.71.3ALLOAllogene Therapeutics3.895 of 5 stars4.53.00.00.03.03.30.6CADLCandel Therapeutics3.0205 of 5 stars3.53.00.00.03.81.70.6OLMAOlema Pharmaceuticals2.5469 of 5 stars3.51.00.00.03.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAWHAscend Wellness 4.00Strong BuyN/AN/AALLOAllogene Therapeutics 2.90Moderate Buy$8.44516.38% UpsideCADLCandel Therapeutics 3.00Buy$21.00306.98% UpsideOLMAOlema Pharmaceuticals 3.00Buy$24.50484.73% UpsideCurrent Analyst Ratings BreakdownLatest AAWH, ALLO, CADL, and OLMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ALLOAllogene TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.005/14/2025ALLOAllogene TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.005/14/2025ALLOAllogene TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$12.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/14/2025OLMAOlema PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $18.005/14/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $22.004/28/2025OLMAOlema PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/11/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAWHAscend Wellness$518.59M0.12$0.04 per share6.64$0.69 per share0.43ALLOAllogene Therapeutics$22K13,620.98N/AN/A$3.04 per share0.45CADLCandel Therapeutics$120K2,154.43N/AN/A$0.44 per share11.73OLMAOlema PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAWHAscend Wellness-$48.21M-$0.40N/AN/AN/A-15.47%-72.18%-9.55%N/AALLOAllogene Therapeutics-$327.27M-$1.23N/AN/AN/AN/A-52.13%-41.29%8/6/2025 (Estimated)CADLCandel Therapeutics-$37.94M-$1.34N/AN/AN/AN/A-629.29%-173.39%8/12/2025 (Estimated)OLMAOlema Pharmaceuticals-$96.65M-$2.01N/AN/AN/AN/A-53.56%-47.86%8/5/2025 (Estimated)Latest AAWH, ALLO, CADL, and OLMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALLOAllogene Therapeutics-$0.28-$0.28N/A-$0.28$0.00 millionN/A5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/A5/13/2025Q1 2025OLMAOlema Pharmaceuticals-$0.49-$0.36+$0.13-$0.36N/AN/A3/18/2025Q4 2024OLMAOlema Pharmaceuticals-$0.63-$0.51+$0.12-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAWHAscend WellnessN/AN/AN/AN/AN/AALLOAllogene TherapeuticsN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAWHAscend Wellness2.611.470.80ALLOAllogene TherapeuticsN/A9.359.35CADLCandel TherapeuticsN/A1.181.18OLMAOlema PharmaceuticalsN/A7.107.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAWHAscend Wellness17.32%ALLOAllogene Therapeutics83.63%CADLCandel Therapeutics13.93%OLMAOlema Pharmaceuticals91.78%Insider OwnershipCompanyInsider OwnershipAAWHAscend Wellness22.38%ALLOAllogene Therapeutics13.20%CADLCandel Therapeutics16.60%OLMAOlema Pharmaceuticals16.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAWHAscend Wellness2,300204.44 million166.44 millionNot OptionableALLOAllogene Therapeutics310218.73 million158.72 millionOptionableCADLCandel Therapeutics6050.10 million18.97 millionOptionableOLMAOlema Pharmaceuticals7068.42 million46.18 millionOptionableAAWH, ALLO, CADL, and OLMA HeadlinesRecent News About These CompaniesQ2 EPS Estimate for Olema Pharmaceuticals Reduced by AnalystJune 6, 2025 | americanbankingnews.comQ2 EPS Forecast for Olema Pharmaceuticals Cut by AnalystJune 4, 2025 | marketbeat.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 | globenewswire.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Wellington Management Group LLPJune 3, 2025 | marketbeat.comH.C. Wainwright Backs Olema Pharmaceuticals (OLMA) as Phase 3 Trials AdvanceMay 30, 2025 | msn.comOlema Pharmaceuticals Selects 90 mg Palazestrant Dose for Phase 3 OPERA-01 and OPERA-02 TrialsMay 29, 2025 | nasdaq.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Millennium Management LLCMay 29, 2025 | marketbeat.comBank of America Corp DE Increases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 29, 2025 | marketbeat.comOlema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual MeetingMay 28, 2025 | globenewswire.comBNP Paribas Financial Markets Makes New $1.13 Million Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 23, 2025 | marketbeat.comOlema Oncology to Participate in Upcoming Investor ConferencesMay 21, 2025 | globenewswire.comWall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?May 21, 2025 | zacks.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Acquired by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comParadigm Biocapital Advisors LP Buys 1,801,370 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 16, 2025 | marketbeat.comOlema Oncology Reports First Quarter 2025 Financial and Operating ResultsMay 13, 2025 | globenewswire.comWhat Role Might (NASDAQ:OLMA) Play in the Changing Landscape of the...May 12, 2025 | kalkinemedia.comOlema Oncology to Participate in Upcoming Investor ConferencesMay 9, 2025 | globenewswire.comWhy Olema Pharmaceuticals, Inc.’s (OLMA) Stock Is Down 5.94%May 6, 2025 | aaii.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comH.C. Wainwright Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)April 30, 2025 | theglobeandmail.comWhy Olema Pharmaceuticals, Inc.’s (OLMA) Stock Is Down 5.78%April 25, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingOuster Soars 27% as DoD Grants First 3D LiDAR Approval for DronesBy Leo Miller | June 14, 2025View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for DronesDave & Buster’s: Short-Covering Rally Signals Big Upside for PLAYBy Thomas Hughes | June 11, 2025View Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAYAAWH, ALLO, CADL, and OLMA Company DescriptionsAscend Wellness OTC:AAWH$0.30 -0.01 (-4.68%) As of 06/13/2025 03:48 PM EasternAscend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.Allogene Therapeutics NASDAQ:ALLO$1.37 +0.03 (+2.24%) Closing price 04:00 PM EasternExtended Trading$1.36 -0.01 (-0.36%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Candel Therapeutics NASDAQ:CADL$5.16 +0.03 (+0.58%) Closing price 04:00 PM EasternExtended Trading$5.16 +0.00 (+0.10%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Olema Pharmaceuticals NASDAQ:OLMA$4.19 +0.02 (+0.48%) Closing price 04:00 PM EasternExtended Trading$4.18 -0.01 (-0.12%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore SoundHound’s AI Growth Story Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
